- Home
- RSKD vs AKBA Comparison
RSKD vs AKBA Comparison
Compare RSKD & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSKD
- AKBA
- Stock Information
- Founded
- RSKD 2012
- AKBA 2007
- Country
- RSKD United States
- AKBA United States
- Employees
- RSKD N/A
- AKBA N/A
- Industry
- RSKD EDP Services
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- RSKD Technology
- AKBA Health Care
- Exchange
- RSKD Nasdaq
- AKBA Nasdaq
- Market Cap
- RSKD 743.4M
- AKBA 729.1M
- IPO Year
- RSKD 2021
- AKBA 2014
- Fundamental
- Price
- RSKD $4.93
- AKBA $1.60
- Analyst Decision
- RSKD Buy
- AKBA Strong Buy
- Analyst Count
- RSKD 8
- AKBA 6
- Target Price
- RSKD $5.91
- AKBA $6.25
- AVG Volume (30 Days)
- RSKD 681.5K
- AKBA 5.6M
- Earning Date
- RSKD 11-12-2025
- AKBA 11-10-2025
- Dividend Yield
- RSKD N/A
- AKBA N/A
- EPS Growth
- RSKD N/A
- AKBA N/A
- EPS
- RSKD N/A
- AKBA N/A
- Revenue
- RSKD $338,838,000.00
- AKBA $225,071,000.00
- Revenue This Year
- RSKD $6.28
- AKBA $53.38
- Revenue Next Year
- RSKD $9.78
- AKBA $30.53
- P/E Ratio
- RSKD N/A
- AKBA N/A
- Revenue Growth
- RSKD 6.54
- AKBA 32.49
- 52 Week Low
- RSKD $3.94
- AKBA $1.49
- 52 Week High
- RSKD $6.00
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- RSKD 55.66
- AKBA 32.12
- Support Level
- RSKD $4.57
- AKBA $1.49
- Resistance Level
- RSKD $4.95
- AKBA $1.65
- Average True Range (ATR)
- RSKD 0.21
- AKBA 0.12
- MACD
- RSKD 0.01
- AKBA 0.01
- Stochastic Oscillator
- RSKD 61.19
- AKBA 18.10
About RSKD Riskified Ltd.
Riskified Ltd has built a next-generation eCommerce risk management platform that allows online merchants to create trusted relationships with their consumers. It generates revenue by granting merchants access to its eCommerce risk management platform and reviewing and approving eCommerce transactions for legitimacy. Its merchants include some of the ecommerce brands including Wayfair, Lastminute.com, SHEIN, and Macy's. Its merchants operate in a variety of verticals, including Payments, Money Transfer & Crypto, Tickets & Travel, Electronics, Home, Fashion & Luxury Goods, General Retail and Food. The company derived maximum revenue from Israel.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.